LUNG - CONSENSUS CO - Pulmonx Corporation

The asset value of Pulmonx Corporation (LUNG), which stands at 3.40 as tracked on the chart, is based on its leadership in severe emphysema therapy via the Zephyr system for pulmonologists. The lack of alternatives for minimally invasive valves allows the brand to maintain pricing power and set premium prices for hospitals. Operational stability is supported by streamlined medical logistics, ensuring the safe and timely delivery of consumables to clinics.

Pulmonx Corporation (LUNG) is developing a high-tech emphysema treatment sector, leveraging strict FDA standards and the expertise of biomedical engineers. This indicator is calculated as the arithmetic mean of target prices from leading analysts, measuring the speed of market adaptation to fundamental news; meanwhile, an upward trajectory in analyst price targets signals an increase in the business's intrinsic value and the company's capitalization potential.